Preparation of Sorafenib tosylate self-emulsified drug delivery system and the effect on combination therapy with Bosutinib against HCT116/SW1417 cells

Bhattacharya, Sankha; Pawde, Datta; Dumpala, Rajesh L.

doi:10.1016/j.rechem.2022.100385

Cited by 5 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of SF and Bosutinib drug was co-loaded in a self-emulsified drug delivery system [ 64 ]. The superior antitumor treatment effect for HCT116/SW1417 by destroying the DNA structure to inhibit cell proliferation was shown.…”

Section: Sf-based Nanomedicinementioning

confidence: 99%

Sorafenib-Based Drug Delivery Systems: Applications and Perspectives

et al. 2023

View full text Add to dashboard Cite

As a Food and Drug Administration (FDA)-approved molecular-targeted chemotherapeutic drug, sorafenib (SF) can inhibit angiogenesis and tumor cell proliferation, leading to improved patient overall survival of hepatocellular carcinoma (HCC). In addition, SF is an oral multikinase inhibitor as a single-agent therapy in renal cell carcinoma. However, the poor aqueous solubility, low bioavailability, unfavorable pharmacokinetic properties and undesirable side effects (anorexia, gastrointestinal bleeding, and severe skin toxicity, etc.) seriously limit its clinical application. To overcome these drawbacks, the entrapment of SF into nanocarriers by nanoformulations is an effective strategy, which delivers SF in a target tumor with decreased adverse effects and improved treatment efficacy. In this review, significant advances and design strategies of SF nanodelivery systems from 2012 to 2023 are summarized. The review is organized by type of carriers including natural biomacromolecule (lipid, chitosan, cyclodextrin, etc.); synthetic polymer (poly(lactic-co-glycolic acid), polyethyleneimine, brush copolymer, etc.); mesoporous silica; gold nanoparticles; and others. Co-delivery of SF and other active agents (glypican-3, hyaluronic acid, apolipoprotein peptide, folate, and superparamagnetic iron oxide nanoparticles) for targeted SF nanosystems and synergistic drug combinations are also highlighted. All these studies showed promising results for targeted treatment of HCC and other cancers by SF-based nanomedicines. The outlook, challenges and future opportunities for the development of SF-based drug delivery are presented.

show abstract

Section: Sf-based Nanomedicinementioning

confidence: 99%